Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345623 | 0.92 | SCN9A (0.41) | SCN9ASCN5AKDM4ECYP1A2CYP2D6 | |
| SCHEMBL3340037 | 0.92 | FFAR4 (0.41) | SCN8ASCN10ASCN9ASCN5ACYP2C9 | |
| SCHEMBL3345443 | 0.91 | KMO (0.44) | SCN8ASCN10ASCN9ASCN5AKDM4E | |
| SCHEMBL3341300 | 0.90 | KMO (0.40) | SCN9ASCN5AKMO | |
| SCHEMBL3341309 | 0.87 | CHRNA7 (0.42) | SCN9ASCN5AKMO | |
| SCHEMBL3341278 | 0.86 | SCN9A (0.43) | SCN9ASCN5AKMOSLC22A12 | |
| SCHEMBL3747199 | 0.83 | SMN1; SMN2 (0.42) | SCN8ASCN10ASCN9ASCN5AKDM4E | |
| SCHEMBL3339524 | 0.83 | KMO (0.44) | SCN9ASCN5AKDM4EKMODHODH | |
| SCHEMBL3345267 | 0.83 | KMO (0.45) | SCN8ASCN10ASCN5ACYP2C9KMO | |
| SCHEMBL3342506 | 0.81 | KMO (0.48) | SCN9ASCN5AKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| WO-2008031500-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | PPARA, PPARD, PPARG | SCN8A 2932/4885SCN10A 1616/4885SCN9A 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.